Glyhart Dosage/Direction for Use

General Dosing Recommendations: Volume depletion should be corrected prior to initiation of dapagliflozin therapy. In addition, renal function should be assessed prior to treatment and periodically thereafter.
May be taken with or without food. (See table.)

Click on icon to see table/diagram/image

Dosage in Elderly Patients: No dosage adjustment is required. However, renal function and risk of volume depletion should be taken into consideration.
Dosage in Patients with Renal Impairment: Type 2 Diabetes Mellitus: No dose adjustment is required for patients with estimated glomerular filtration rate (eGFR) ≥45 mL/min/1.73 m².
As the glycemic efficacy is dependent on renal function, dapagliflozin should not be initiated to improve glycemic control in patients with an eGFR persistently <60 mL/min/1.73 m² and should be discontinued at eGFR persistently <45 mL/min/1.73 m².
Dapagliflozin is contraindicated in patients with an eGFR <30 mL/min/1.73 m², end-stage renal disease (ESRD) or patients on dialysis.
Heart Failure: No dose adjustment is required based on renal function. Dapagliflozin is contraindicated in patients with an eGFR <30 mL/min/1.73 m², end-stage renal disease (ESRD) or patients on dialysis.
Dosage in Patients with Hepatic Impairment: No dose adjustment is necessary for patients with mild or moderate hepatic impairment. In patients with severe hepatic impairment, a starting dose of 5 mg is recommended. The dose may be increased to 10 mg if well tolerated.
Dosage in Patients at Risk for Volume Depletion: In patients at risk for volume depletion due to coexisting conditions, a starting dose of 5 mg may be appropriate.